4//SEC Filing
Altimmune, Inc. 4
Accession 0000899243-17-012356
$ALTCIK 0001326190operating
Filed
May 7, 8:00 PM ET
Accepted
May 8, 8:32 PM ET
Size
8.6 KB
Accession
0000899243-17-012356
Insider Transaction Report
Form 4
Altimmune, Inc.NASDAQ:ALT
CZEREPAK ELIZABETH
CFO and EVP Corp. Development
Transactions
- Award
Stock Option (option to buy)
2017-05-04+178,595→ 178,595 totalExercise: $13.35Exp: 2025-05-27→ Common Stock, par value $0.0001 (178,595 underlying) - Award
Stock Option (option to buy)
2017-05-04+18,727→ 18,727 totalExercise: $13.38Exp: 2016-04-07→ Common Stock, par value $0.0001 (18,727 underlying)
Footnotes (3)
- [F1]The option is currently exercisable to purchase 119,207 shares of the Issuer's common stock, par value $0.0001 ("Common Stock"). The option to purchase the remaining 59,388 shares of Common Stock will vest in equal installments on a monthly basis until 4/7/2019.
- [F2]Acquired pursuant to the Agreement and Plan of Merger, dated as of January 18, 2017 (as amended on March 29, 2017, the "Merger Agreement"), pursuant to which a wholly-owned subsidiary of the Issuer merged with and into Altimmune, Inc. ("Altimmune"). Pursuant to the Merger Agreement the Issuer assumed all outstanding options to purchase shares of Altimmune capital stock on a 0.749106:1 basis upon closing of the merger.
- [F3]The option is currently exercisable to purchase 6,250 shares of the Issuer's Common Stock. An additional 25% of the option will vest on each of 3/2/2018, 3/2/2019, and 3/2/2020.
Documents
Issuer
Altimmune, Inc.
CIK 0001326190
Entity typeoperating
IncorporatedDE
Related Parties
1- filerCIK 0001326190
Filing Metadata
- Form type
- 4
- Filed
- May 7, 8:00 PM ET
- Accepted
- May 8, 8:32 PM ET
- Size
- 8.6 KB